In vitro studies demonstrated enhanced uptake of siRNA-Ch-HAD NPs by cancer cells, as indicated by the significant CD44 protein expression following the receptors’ activation, and superior silencing efficiency compared to a commercial transfection reagent (HiPerFect) and NPs with HA instead of HAD (i.e., siRNA-Ch-HA NPs). This evidence concerns the gene CD44 and cancer.